<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04274751</url>
  </required_header>
  <id_info>
    <org_study_id>CASVE PI-19-1428</org_study_id>
    <nct_id>NCT04274751</nct_id>
  </id_info>
  <brief_title>Comparison of Transaxillary and Transfemoral Fully-percutaneous Approaches for Transcatheter Aortic Valve Implantation</brief_title>
  <acronym>TRANSAX</acronym>
  <official_title>Comparison of Transaxillary and Transfemoral Fully-percutaneous Approaches for Transcatheter Aortic Valve Implantation: The TRANSAX Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ignacio J. Amat Santos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clínico Universitario de Valladolid</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective, observational study to compare the outcomes of patient receiving TAVI through
      transfemoral and transaxillary fully percutaneous approach adjusting for main baseline
      differences.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic stenosis (AS) is the most frequently treated heart valve disease in our society.
      Transcatheter aortic valve implantation (TAVI) was originally described through an antegrade
      transeptal route by Cribier and colleagues in 2002. Because of the complexity of the
      procedure and risks of damaging the mitral apparatus, this approach was abandoned in favor of
      less challenging alternatives, with transfemoral (TF) route as primary option. Nevertheless,
      the TF approach is not feasible or of high risk in between 15 and 35% of the patients and
      vascular complications have been shown to be an independent predictor of death warranting
      alternative access techniques for TAVI. In this regard, the transapical, direct aortic,
      transcarotid, transcaval, and transubclavian/transaxillary (TSc) implantation routes
      currently serve as alternative access options. The TSc approach was initially used in
      selected cases. However, recent series suggest that TSc may provide better outcomes than
      alternative routes when TF is inadequate. Additionally, same studies suggest that, as
      compared to TF approach, TSc TAVI may present lower rate of vascular complications with
      comparable rates of other major outcomes despite the worse baseline profile of patients who
      are considered inappropriate for TF procedures. Moreover, fully-percutaneous TSc approach can
      be successfully performed with low rate of complications as was recently proposed by some
      authors. However, comparisons have been based in small series of cases, most of them with
      former iteration of TAVI devices, and a formal prospective comparison has never been
      performed. Therefore, our aim is to gather all cases of fully-percutaneous TSc and TF
      approaches for TAVI in Spain and Portugal and compare the standardized safety and efficacy
      endpoints through a matched analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>30-day death, stroke or embolic events, PVE or sepsis</measure>
    <time_frame>30 day</time_frame>
    <description>Combined endpoint of death, stroke or embolic events, PVE or sepsis at 30-day follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1-year death, stroke or embolic events, PVE or sepsis</measure>
    <time_frame>1 year</time_frame>
    <description>Combined endpoint of death, stroke or embolic events, PVE or sepsis at 1-year follow up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intraprocedural Vascular complications</measure>
    <time_frame>Intraprocedural</time_frame>
    <description>Intraprocedural Vascular complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In-hospital Vascular complications</measure>
    <time_frame>7-days</time_frame>
    <description>In-hospital Vascular complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short term complications related to the approach.</measure>
    <time_frame>30-days</time_frame>
    <description>Short term complications related to the approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mid term complications related to the approach.</measure>
    <time_frame>1-year</time_frame>
    <description>Mid term complications related to the approach.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Transaxillary</arm_group_label>
    <description>TAVI, transaxillary approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transfemoral</arm_group_label>
    <description>TAVI, transfemoral approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter aortic valve implantation</intervention_name>
    <description>Transcatheter aortic valve implantation</description>
    <arm_group_label>Transaxillary</arm_group_label>
    <arm_group_label>Transfemoral</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who underwent TAVI through transfemoral of transaxillary fully-percutaneous
        approach between January 2017 and January 2019.

        All-comers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who underwent TAVI through transfemoral of transaxillary fully-percutaneous
             approach between January 2017 and January 2019.

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ignacio J Amat Santos, Dr.</last_name>
    <phone>983420000</phone>
    <email>ijamat@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio J. Amat Santos, Dr.</last_name>
      <email>ijamat@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Brennan JM, Holmes DR, Sherwood MW, Edwards FH, Carroll JD, Grover FL, Tuzcu EM, Thourani V, Brindis RG, Shahian DM, Svensson LG, O'Brien SM, Shewan CM, Hewitt K, Gammie JS, Rumsfeld JS, Peterson ED, Mack MJ. The association of transcatheter aortic valve replacement availability and hospital aortic valve replacement volume and mortality in the United States. Ann Thorac Surg. 2014 Dec;98(6):2016-22; discussion 2022. doi: 10.1016/j.athoracsur.2014.07.051. Epub 2014 Oct 29.</citation>
    <PMID>25443009</PMID>
  </reference>
  <reference>
    <citation>Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002 Dec 10;106(24):3006-8.</citation>
    <PMID>12473543</PMID>
  </reference>
  <reference>
    <citation>Kurra V, Schoenhagen P, Roselli EE, Kapadia SR, Tuzcu EM, Greenberg R, Akhtar M, Desai MY, Flamm SD, Halliburton SS, Svensson LG, Sola S. Prevalence of significant peripheral artery disease in patients evaluated for percutaneous aortic valve insertion: Preprocedural assessment with multidetector computed tomography. J Thorac Cardiovasc Surg. 2009 May;137(5):1258-64. doi: 10.1016/j.jtcvs.2008.12.013.</citation>
    <PMID>19380001</PMID>
  </reference>
  <reference>
    <citation>Caceres M, Braud R, Roselli EE. The axillary/subclavian artery access route for transcatheter aortic valve replacement: a systematic review of the literature. Ann Thorac Surg. 2012 Mar;93(3):1013-8. doi: 10.1016/j.athoracsur.2011.10.056. Epub 2012 Jan 5. Review.</citation>
    <PMID>22226233</PMID>
  </reference>
  <reference>
    <citation>Walther T, Simon P, Dewey T, Wimmer-Greinecker G, Falk V, Kasimir MT, Doss M, Borger MA, Schuler G, Glogar D, Fehske W, Wolner E, Mohr FW, Mack M. Transapical minimally invasive aortic valve implantation: multicenter experience. Circulation. 2007 Sep 11;116(11 Suppl):I240-5.</citation>
    <PMID>17846311</PMID>
  </reference>
  <reference>
    <citation>Bapat V, Khawaja MZ, Attia R, Narayana A, Wilson K, Macgillivray K, Young C, Hancock J, Redwood S, Thomas M. Transaortic Transcatheter Aortic valve implantation using Edwards Sapien valve: a novel approach. Catheter Cardiovasc Interv. 2012 Apr 1;79(5):733-40. doi: 10.1002/ccd.23276. Epub 2011 Sep 26.</citation>
    <PMID>21805602</PMID>
  </reference>
  <reference>
    <citation>Modine T, Sudre A, Delhaye C, Fayad G, Lemesle G, Collet F, Koussa M. Transcutaneous aortic valve implantation using the left carotid access: feasibility and early clinical outcomes. Ann Thorac Surg. 2012 May;93(5):1489-94. doi: 10.1016/j.athoracsur.2012.01.030. Epub 2012 Mar 28.</citation>
    <PMID>22464036</PMID>
  </reference>
  <reference>
    <citation>Greenbaum AB, O'Neill WW, Paone G, Guerrero ME, Wyman JF, Cooper RL, Lederman RJ. Caval-aortic access to allow transcatheter aortic valve replacement in otherwise ineligible patients: initial human experience. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2795-804. doi: 10.1016/j.jacc.2014.04.015. Epub 2014 May 7.</citation>
    <PMID>24814495</PMID>
  </reference>
  <reference>
    <citation>Schofer N, Deuschl F, Conradi L, Lubos E, Schirmer J, Reichenspurner H, Blankenberg S, Treede H, Schäfer U. Preferential short cut or alternative route: the transaxillary access for transcatheter aortic valve implantation. J Thorac Dis. 2015 Sep;7(9):1543-7. doi: 10.3978/j.issn.2072-1439.2015.07.27. Review.</citation>
    <PMID>26543600</PMID>
  </reference>
  <reference>
    <citation>Moat NE, Ludman P, de Belder MA, Bridgewater B, Cunningham AD, Young CP, Thomas M, Kovac J, Spyt T, MacCarthy PA, Wendler O, Hildick-Smith D, Davies SW, Trivedi U, Blackman DJ, Levy RD, Brecker SJ, Baumbach A, Daniel T, Gray H, Mullen MJ. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol. 2011 Nov 8;58(20):2130-8. doi: 10.1016/j.jacc.2011.08.050. Epub 2011 Oct 20.</citation>
    <PMID>22019110</PMID>
  </reference>
  <reference>
    <citation>Amat-Santos IJ, Rojas P, Gutiérrez H, Vera S, Castrodeza J, Tobar J, Goncalves-Ramirez LR, Carrasco M, Catala P, San Román JA. Transubclavian approach: A competitive access for transcatheter aortic valve implantation as compared to transfemoral. Catheter Cardiovasc Interv. 2018 Nov 1;92(5):935-944. doi: 10.1002/ccd.27485. Epub 2018 Jan 3.</citation>
    <PMID>29314570</PMID>
  </reference>
  <reference>
    <citation>Garcia DC, Benjo A, Cardoso RN, Macedo FY, Chavez P, Aziz EF, Herzog E, Alam M, de Marchena E. Device stratified comparison among transfemoral, transapical and transubclavian access for Transcatheter Aortic Valve Replacement (TAVR): a meta-analysis. Int J Cardiol. 2014 Mar 15;172(2):e318-21. doi: 10.1016/j.ijcard.2013.12.162. Epub 2014 Jan 9.</citation>
    <PMID>24485611</PMID>
  </reference>
  <reference>
    <citation>Schäfer U, Deuschl F, Schofer N, Frerker C, Schmidt T, Kuck KH, Kreidel F, Schirmer J, Mizote I, Reichenspurner H, Blankenberg S, Treede H, Conradi L. Safety and efficacy of the percutaneous transaxillary access for transcatheter aortic valve implantation using various transcatheter heart valves in 100 consecutive patients. Int J Cardiol. 2017 Apr 1;232:247-254. doi: 10.1016/j.ijcard.2017.01.010. Epub 2017 Jan 7.</citation>
    <PMID>28118931</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2020</study_first_posted>
  <last_update_submitted>February 16, 2020</last_update_submitted>
  <last_update_submitted_qc>February 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clínico Universitario de Valladolid</investigator_affiliation>
    <investigator_full_name>Ignacio J. Amat Santos</investigator_full_name>
    <investigator_title>Head of Interventional Cardiology Unit</investigator_title>
  </responsible_party>
  <keyword>Transcatheter aortic valve Implantation (TAVI)</keyword>
  <keyword>Transaxillary approach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

